Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Licenses SNaPIT Genotyping Technology from HiberGen

NEW YORK, July 9 - Sequenom has agreed to exclusively license HiberGen's SNaPIT genotyping technology for use with its MassArray mass spectrometry platform, the companies said Monday.

The license will allow San Diego-based Sequenom to develop and commercialize reagents and software for the MassArray system using HiberGen's technology. In return, Sequenom will pay HiberGen a license fee and royalties from sales of any SNaPIT-related products that Sequenom develops.

HiberGen, a population genomics and genotyping business based in Dublin, Ireland, will continue to use its SNaPIT technology to identify genetic markers associated with disease. The company also hopes to find other partners to license the SNaPIT technology for additional applications.

"Sequenom's reputation as a leader in SNP analysis, together with its strong links with academic and research centers make them an ideal partner for HiberGen as we pursue our strategy of out-licensing SNaPIT for use on a variety of detection platforms," Maurice Treacy, Chief Executive of HiberGen, said in a statement.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.